HyperAIHyperAI

Command Palette

Search for a command to run...

Chemify Secures Over $50 Million in Oversubscribed Series B to Accelerate Global Expansion of Digital Chemistry and AI-Powered Drug Discovery

Chemify, a Glasgow-based digital chemistry company, has raised over $50 million in an oversubscribed Series B funding round, marking a significant milestone in its mission to transform chemical discovery through advanced digital technologies. The investment will fuel the company’s global expansion and accelerate the development of its AI-powered platform designed to streamline and enhance the process of molecule design and synthesis planning. The round was led by a consortium of strategic investors, including leading venture capital firms and industry partners with deep expertise in life sciences and technology. The oversubscription reflects strong market confidence in Chemify’s innovative approach to digital chemistry, which leverages machine learning, quantum chemistry, and data-driven modeling to predict reaction outcomes, optimize synthetic routes, and reduce the time and cost of drug discovery. Chemify’s platform enables chemists to explore vast chemical spaces with unprecedented speed and accuracy, offering a powerful tool for pharmaceutical and biotech companies, as well as academic research institutions. By integrating real-world chemical data with predictive algorithms, the company is helping to bridge the gap between theoretical chemistry and practical application. The new capital will be used to expand the company’s engineering and research teams, enhance its core platform, and scale operations in key international markets, including North America, Europe, and Asia. Chemify also plans to strengthen partnerships with major pharmaceutical companies and research organizations to co-develop next-generation tools for drug discovery and materials science. Founded in 2018, Chemify has quickly established itself as a leader in the digital chemistry space, earning recognition for its user-friendly interface, high predictive accuracy, and commitment to open science principles. The company’s success comes at a time when the pharmaceutical industry is under increasing pressure to deliver new treatments faster and more efficiently, and digital tools are becoming essential in meeting that challenge. With this latest funding, Chemify is poised to play a central role in the future of chemical innovation, helping scientists turn complex challenges into tangible solutions.

Related Links